Results 161 to 170 of about 1,185,385 (293)

RoundMi: A quantitative method to analyze mitochondrial morphology in mitotic cells

FEBS Open Bio, EarlyView.
RoundMi is a workflow for rapid analysis of mitochondrial morphology in mitotic cells. By combining adaptive preprocessing with automated segmentation and quantification, it enables accurate measurements from single focal plane images, reducing acquisition time and computational demands while remaining compatible with high‐throughput fixed and live ...
Elmira Parvindokht Bararpour, Christine Volmert, Valentina Piano   +2 more
wiley   +1 more source

Erratum: 238 The Translational Science Promotion and Research Capacity (T-SPARC) framework: Developing institutional capacity for translational science - CORRIGENDUM. [PDF]

J Clin Transl Sci
Sperling J, Quenstedt S, Muhigaba P, Joseph McClernon F, Glauber K, Ghanem E, Saxena T, Rodriguez V, Sanchez C.   +8 more
europepmc   +1 more source

The Translational Science Benefits Model: A New Framework for Assessing the Health and Societal Benefits of Clinical and Translational Sciences [PDF]

, 2018
American Academy of Pediatrics, American College of Obstetricians and Gynecologists, Bornmann, Brownson, Brownson, Buxton, Colledge, Cooksy, Dalkey, Dembe, Donovan, Doran, Glasgow, Glasziou, Guthrie, Hanney, Hazelkorn, Hsu, Institute of Medicine, Kang, Kuruvilla, Mayne, McNicholas, Morrissey, Morrissey, National Institutes of Health, Rubio, Rubio, Sarli, Searles, Secura, Smith, Trochim, Wang, Weiss, Woolf   +35 more
core   +2 more sources

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

FEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová, Grigorii Rakhalskii, Miroslav Almáši   +2 more
wiley   +1 more source

Taking the Translational Science Benefits Model from concept to operationalization: opportunities and challenges in defining impact using the Translational Science Benefits Model. [PDF]

Front Public Health
Sperling J, Ghanem E, Quenstedt S, Saxena T.   +3 more
europepmc   +1 more source

Natural Products as Geroprotective Modulators in Diabetic Nephropathy: A Mechanistic Framework Integrating Aging Hallmarks and the AMPK–SIRT1–Nrf2 Axis

Aging and Cancer, EarlyView.
Natural products target the aging kidney in diabetic nephropathy by restoring the AMPK–SIRT1–Nrf2 axis, reducing oxidative stress, inflammation, fibrosis, and cellular senescence while enhancing mitochondrial biogenesis and antioxidant defenses.
Sherif Hamidu, Latif Adams, Eunice Ampem‐Danso, Justice Kumi, Abigail Aning, Fatima Hamidu, Mustapha Abdul Mumin Mohammed, Ayuba Nii Darku Ankrah, Seth Kwabena Amponsah   +8 more
wiley   +1 more source

A Survey Study of Roadblocks in Translational Science. [PDF]

Clin Transl Sci
Kanwal F, Amos CI, Sippel KH, Neuhauser C, Harrison A, Dickinson ME, Minard C, Beech BM.   +7 more
europepmc   +1 more source

Aging Is a Key Driver for Adult Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley   +1 more source

Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science. [PDF]

Clin Transl Sci
Walley AH, Dupuis LN, Woodahl EL, Killam SR.   +3 more
europepmc   +1 more source

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese   +7 more
wiley   +1 more source